Federal Courts Uphold State 340B Protection Laws Against Pharmaceutical Challenges
核心洞察
Federal courts in Mississippi and Maine have rejected pharmaceutical companies' attempts to block state laws protecting 340B drug pricing programs.
AbbVie (搜索) lost its bid for a preliminary injunction against Mississippi's 340B protection law, with the U.S. Court of Appeals for the 5th Circuit upholding the lower court decision.
Novartis and AbbVie (搜索) were denied their request to temporarily block Maine's contract pharmacy law that prohibits manufacturers from restricting 340B drug access.
Federal courts have delivered significant victories for healthcare providers in two separate cases, rejecting pharmaceutical companies' legal challenges to state laws designed to protect the 340B drug pricing program. The rulings underscore growing judicial support for state-level protections of the federal discount drug program that serves safety-net healthcare providers.
Mississippi Court Victory
The U.S. Court of Appeals for the 5th Circuit upheld a Mississippi court decision denying drugmaker AbbVie (搜索)'s request for a preliminary injunction against the state's 340B protection law. The federal appellate court's ruling represents a significant legal setback for pharmaceutical manufacturers seeking to challenge state-level 340B protections.
A coalition of major hospital organizations rallied to defend the Mississippi law, filing an amicus brief in support of the state's position. The coalition included the American Hospital Association (搜索), 340B Health (搜索), the Mississippi Hospital Association (搜索), the Rural Hospital Alliance (搜索), and the American Society of Health-System Pharmacists (搜索).
In their legal brief, hospital groups emphasized that the 340B program serves a critical public health function by helping safety-net providers deliver affordable care to vulnerable communities. The organizations argued that drugmaker restrictions fundamentally undercut the program's original legislative intent.
Maine Legal Challenge Fails
In a parallel development, a federal judge from the U.S. District Court for the District of Maine rejected attempts by Novartis AG and AbbVie (搜索) Inc. to temporarily block Maine's Protect Health Care for Rural and Underserved Communities Act. The Tuesday ruling denied the drugmakers' bid for preliminary relief while their underlying lawsuits continue.
Maine's law specifically prohibits manufacturers from restricting the acquisition of drugs discounted through the federal 340B program. The pharmaceutical companies had argued that the state law was preempted by federal 340B regulations, but the court disagreed with their preliminary injunction request.
Industry Impact
These court decisions represent the latest setbacks for pharmaceutical manufacturers in their broader legal campaign against state-level 340B protections. The rulings suggest federal courts are increasingly skeptical of industry arguments that state laws interfere with federal drug pricing programs.
The 340B program requires pharmaceutical manufacturers to provide discounts on outpatient drugs to eligible healthcare organizations that serve high numbers of uninsured and low-income patients. Safety-net hospitals and other covered entities use these savings to expand services and improve care access in underserved communities.